摘要
[目的 ]探讨游离前列腺特异性抗原 (F -PSA)、总前列腺特异性抗原 (T -PSA)及F -PSA和T -PSA比值 (F/T) ,对良性前列腺增生 (BPH)和前列腺癌 (PCa)患者的鉴别价值。 [方法 ]采用微粒子酶免疫化学发光技术 ,测定 32例健康体检者、12 0例BPH患者和 32例PCa患者的血清F-PSA、T -PSA ,并计算其比值F/T。 [结果 ]正常对照组、BPH组与PCa组F -PSA依次为 (0 .4± 0 .3)、(2 .3± 2 .4 )和 (5 .9± 5 .7) μg/L ,T -PSA依次为 (1.5± 1.5 )、(11.7± 8.8)和 (33.9± 2 9.5 ) μg/L ,各组间差异显著 (P <0 .0 1)、F/T值BPH组高于PCa组 ,但标准差过大未有显著性差异(P >0 .0 5 )。在T -PSA诊断灰区 (4.0～ 2 5 .0 μg/L)中BPH组F/T值高于PCa组 (P <0 .0 5 ) ,并且以T -PSA >4 .0 μg/L、F/T比值 <15 .0 %为界值时效果较好。 [结论 ]联合应用T -PSA、F -PSA及F/T诊断PCa明显优于单用T -PSA。
The authors evaluated the use of free prostate specific antigen(F-PSA), total prostate specific antigen (T-PSA) as well as the ratio of F-PSA to T-PSA (F/T) to improve the discrimination between patients with benign prostatic hyperplasia (BPH) and those with prostate cancer (PCa), especially in patients whose T-PSA values among 4～25 μg/L. Three groups: healthy males 32, males with BPH 120 and males with PCa 32 were included. F-PSA and T-PSA were measured with microparticle enzyme chemiluminescent immunoassay (MECIA) and the F/T ratio was calculated. T-PSA and F-PSA of groups with PCa and BPH and of the healthy persons were (33.9±29.5) μg/L?(5.9±5.7) μg/L,(11.7±8.8) μg/L?(2.3±2.4) μg/L and (1.5±1.5) μg/L ?(0.4±0.3) μg/L respectively with significantly differences. The F/T ratio of group BPH was higher than those of PCa, but without significant difference. However the F/T ratio of group BPH was significantly higher than that of PCa in the zone in which the T-PSA changed in (4.0～25.0) μg/L(the diagnostic gray zone). [Conclusion] Detection of both F-PSA and T-PSA is helpful to differentiate the patients with PCa from those with BPH.
出处
《大连医科大学学报》
CAS
2002年第4期272-274,共3页
Journal of Dalian Medical University
